Letter: Upadacitinib-Induced Amenorrhea: A Rare Adverse Effect in Atopic Dermatitis Treatment

Abstract

Get full access to this article

View all access options for this article.

References

Guttman-Yassky

, Renert-Yuval

, Brunner

. Atopic dermatitis. Lancet (London, England). 2025; 405(10478):583–596.

Flohr

, Rosala-Hallas

, Jones

, et al.; TREAT Trial Investigators. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): A multicentre parallel group assessor-blinded clinical trial. Br J Dermatol. 2023; 189(6):674–684.

Paller

, Mendes-Bastos

, Siegfried

, et al. Upadacitinib in adolescents with moderate to severe atopic dermatitis: Analysis of 3 phase 3 randomized clinical trials through 76 weeks. JAMA Dermatol. 2024; 160(12):1304–1313.

Wan

, Jia

, Xia

, et al. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis. Dermatol Ther. 2022; 35(9):e15636.

Teng

, Tang

, Fan

, et al. Amenorrhea in an adolescent female as a rare adverse event of upadacitinib treatment for atopic dermatitis. Patient Prefer Adherence. 2024; 18:2307–2310.